Scancell gives positive update on melanoma treatment data
2nd Jun 2015 12:19
Biopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The data showed that all 16 patients with re
Read moreScancell Holdings sees annual losses widen
4th Sep 2014 11:23
Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, made an annual loss of £2.22m in the year to 30 April compared to £1.9m last year. The company development spending increased due to additional costs in pre-clinical studies for a new platform technology, while adm
Read moreScancell Holdings ImmunoBody technology receives US approval
6th Jun 2014 08:54
AIM-listed Pharmaceuticals group Scancell Holdings announced a patent for its DNA ImmunoBody technology has been approved in the US. The patent has been granted by the United States Patent and Trademark Office (USPTO) and covers Scancell's DNA ImmunoBody platform technology. This patent is expect
Read moreScancell reports encouraging results of melanoma treatment
2nd Jun 2014 11:08
Scancell's shares advanced after announcing "encouraging results" from the clinical trial of its SCIB1 ImmunoBody drug for the treatment of stage III/IV melanoma. The phase 1 and 2 trial tested the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electropo
Read morePrezzo exec slices off 200,000 shares
22nd Oct 2013 16:26
Kuldip Sehmi, an Executive Director at Italian restaurant chain Prezzo, on Monday traded in 200,000 shares, reducing his stake to 682,244 shares, equal to 0.29 per cent of the issued share capital. Sehmi, who is responsible for the day to day running of approximately half the Prezzo estate, sold t
Read moreScancell reports progress across a number of trials
1st Oct 2013 10:02
Scancell, which develops novel immunotherapies for the treatment of cancer, on Tuesday revealed that four out of the six evaluable patients treated with either the 2mg or 4mg dose of its SCIB1 drug still remain alive. It said the mean survival time in this group of five Stage IV and one Stage IIIb
Read moreScancell secures Australian patent
3rd Sep 2013 14:13
Scancell said it had received a patent for its DNA ImmunoBody treatment in Australia. Australia is the first jurisdiction to approve the DNA patent. Scancell said it was an important step to comprehensively protecting the technology. Scancell specialises in treatments to encourage the immune sys
Read moreSABMilller Chairman sells over 11m pounds in shares
23rd Jul 2013 16:21
Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so
Read moreScancell shares healthy following patent approval award in Japan
6th Feb 2013 11:06
Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan. The same patent has already been approved in the US, Europe and Australia. Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This
Read moreSector movers: Pharmaceuticals under the weather as AstraZeneca takes a hit
31st Jan 2013 15:04
The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices. The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at consta
Read moreSix month operating loss increases slightly at Scancell
31st Jan 2013 14:33
AIM-listed medical company Scancell has published its unaudited interim results for the six month period to October 31st, showing an overall operating loss of 989,981 pounds. This compared to a loss of £941,674 in the corresponding period in 2011. The cash at bank on October 31st was £2.6m compar
Read moreScancell Holdings updates on clinical trial of melanoma vaccine
29th Jan 2013 09:05
Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma. The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection. The trial is being cond
Read more